PTGS2 and peptic ulcer disease: Selective COX-2 inhibitors, as a type of non-steroidal anti-inflammatory drug (NSAID), are able to directly target cyclooxygenase-2 (COX-2) an enzyme responsible for inflammation and pain leading to reduce the risk of peptic ulceration.